Cargando…

Associations between maternal characteristics and pharmaceutical treatment of gestational diabetes: an analysis of the UK Born in Bradford (BiB) cohort study

OBJECTIVES: To identify the maternal characteristics associated with pharmaceutical treatment of gestational diabetes mellitus (GDM). DESIGN: Prospective birth cohort study. SETTING: Bradford, UK. PARTICIPANTS: 762 women from the Born in Bradford (BiB) cohort who were treated for GDM in a singleton...

Descripción completa

Detalles Bibliográficos
Autores principales: Martine-Edith, Gilberte, Johnson, William, Hunsicker, Eugenie, Hamer, Mark, Petherick, Emily S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8572403/
https://www.ncbi.nlm.nih.gov/pubmed/34732497
http://dx.doi.org/10.1136/bmjopen-2021-053753
Descripción
Sumario:OBJECTIVES: To identify the maternal characteristics associated with pharmaceutical treatment of gestational diabetes mellitus (GDM). DESIGN: Prospective birth cohort study. SETTING: Bradford, UK. PARTICIPANTS: 762 women from the Born in Bradford (BiB) cohort who were treated for GDM in a singleton pregnancy. BiB cohort participants were recruited from 2007 to 2010. All women booked for delivery were screened for GDM between 26 and 28 weeks of gestation using a 75 g 2-hour oral glucose tolerance test (OGTT). OUTCOME MEASURE: GDM treatment type: lifestyle changes advice (lifestyle changes), lifestyle changes advice with supplementary insulin (insulin) and lifestyle changes advice with supplementary metformin (metformin). RESULTS: 244 (32%) women were prescribed lifestyle changes advice alone while 518 (68%) were offered supplemental pharmaceutical treatment. The odds of receiving pharmaceutical treatment relative to lifestyle changes advice alone were increased for mothers who were obese (OR 4.6, 95% CI 2.8 to 7.5), those who smoked (OR 2.6, 95% CI 1.2 to 5.5) and had higher fasting glucose levels at OGTT (OR 2.1, 95% CI 1.6 to 2.7). The odds of being prescribed pharmaceutical treatment rather than lifestyle changes advice were lower for Pakistani women (OR 0.7, 95% CI 0.4 to 1.0)) than White British women. Relative to insulin treatment, metformin was more likely to be offered to obese women than normal weight women (relative risk ratio, RRR 3.2, 95% CI 1.3 to 7.8) and less likely to be prescribed to women with higher fasting glucose concentrations at OGTT (RRR 0.3, 95% CI 0.2 to 0.6). CONCLUSIONS: In the BiB cohort, GDM pharmaceutical treatment tended to be prescribed to women who were obese, White British, who smoked and had more severe hyperglycaemia. The characteristics of metformin-treated mothers differed from those of insulin-treated mothers as they were more likely to be obese but had lower glucose concentrations at diagnosis.